BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sarah Aebersold Sells 711 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Sarah Aebersold sold 711 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $22.23, for a total transaction of $15,805.53. Following the completion of the transaction, the insider now directly owns 78,721 shares of the company's stock, valued at $1,749,967.83. This represents a 0.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Sarah Aebersold also recently made the following trade(s):

• On Tuesday, June 10th, Sarah Aebersold sold 235 shares of BioLife Solutions stock. The stock was sold at an average price of $23.70, for a total transaction of $5,569.50.
• On Wednesday, May 28th, Sarah Aebersold sold 217 shares of BioLife Solutions stock. The stock was sold at an average price of $22.46, for a total transaction of $4,873.82.
• On Wednesday, April 9th, Sarah Aebersold sold 210 shares of BioLife Solutions stock. The stock was sold at an average price of $20.11, for a total transaction of $4,223.10.
• On Tuesday, April 1st, Sarah Aebersold sold 5,771 shares of BioLife Solutions stock. The shares were sold at an average price of $22.66, for a total transaction of $130,770.86.

BioLife Solutions Stock Down 1.4%

Shares of BioLife Solutions stock traded down $0.30 during midday trading on Friday, reaching $21.22. 547,867 shares of the company's stock traded hands, compared to its average volume of 409,500. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -73.17 and a beta of 1.82. The company's 50 day simple moving average is $22.71 and its 200 day simple moving average is $24.78. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.74 and a current ratio of 4.73. BioLife Solutions, Inc. has a 52 week low of $18.70 and a 52 week high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. The business had revenue of $23.94 million for the quarter, compared to the consensus estimate of $22.22 million. BioLife Solutions had a negative net margin of 11.81% and a negative return on equity of 0.66%. Equities analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BLFS has been the subject of a number of research reports. Wall Street Zen lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.17.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. D.A. Davidson & CO. raised its holdings in BioLife Solutions by 1.3% in the 4th quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider's stock worth $1,069,000 after acquiring an additional 519 shares during the period. Sei Investments Co. raised its holdings in BioLife Solutions by 0.5% in the 1st quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider's stock worth $2,695,000 after acquiring an additional 547 shares during the period. Rhumbline Advisers raised its holdings in BioLife Solutions by 0.7% in the 1st quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider's stock worth $1,901,000 after acquiring an additional 566 shares during the period. GAMMA Investing LLC raised its holdings in BioLife Solutions by 18.6% in the 1st quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after acquiring an additional 663 shares during the period. Finally, 1620 Investment Advisors Inc. raised its holdings in BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after acquiring an additional 675 shares during the period. Institutional investors own 93.24% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.